A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Source:http://linkedlifedata.com/resource/pubmed/id/19509177

Clin. Cancer Res. 2009 Jun 15 15 12 4207-12

Download in:

View as

Triples

General Info

PMID
19509177